Orion Oyj Class B ORNBV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €80.90
- Day Range
- €79.45–81.45
- 52-Week Range
- €56.50–84.60
- Bid/Ask
- €80.75 / €80.85
- Shares Outstanding
- 140.37M
- Market Cap
- €11.34B
- Volume/Avg
- 143,026 / 158,594
Key Statistics
- Price/Earnings (Normalized)
- 18.86
- Price/Sales
- 5.54
- Dividend Yield (Trailing)
- 2.13%
- Dividend Yield (Forward)
- 2.23%
- Dividend Payment Schedule
- Apr, Oct
- Total Yield
- 2.13%
Company Profile
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 4,154
- Website
- https://www.orion.fi
Valuation
|
Metric
|
ORNBV
|
|---|---|
Price/Earnings (Normalized) | 18.86 |
Price/Book Value | 8.98 |
Price/Sales | 5.54 |
Price/Cash Flow | 16.74 |
Price/Earnings
ORNBV
Financial Strength
|
Metric
|
ORNBV
|
|---|---|
Quick Ratio | 1.48 |
Current Ratio | 2.64 |
Interest Coverage | 194.84 |
Quick Ratio
ORNBV
Profitability
|
Metric
|
ORNBV
|
|---|---|
Return on Assets (Normalized) | 31.37% |
Return on Equity (Normalized) | 52.28% |
Return on Invested Capital (Normalized) | 42.08% |
Return on Assets
ORNBV
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|g>Z?<x< | LOCK|#G& | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|^!!HWP | LOCK|hl | $617B | |||
| AbbVie Inc
ABBV
| LOCK|RVktK% | LOCK|Cl | $464B | |||
| Merck & Co Inc
MRK
| LOCK|?Jd!DK | LOCK|cS^ | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|n@h<K&#X | LOCK|!! | $333B | |||
| Novartis AG ADR
NVS
| LOCK|?m$%p@< | LOCK|RS& | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|M$@N^n> | LOCK|^? | $243B | |||
| Amgen Inc
AMGN
| LOCK|xHHM>#$ | LOCK|GR> | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|@hS>&! | LOCK|^%$ | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|PH!?Db | LOCK|ZK | $165B |
United States